通过肾移植改善罕见代谢性疾病:赖氨酸尿性蛋白不耐受患者一例病例报告
赖氨酸尿性蛋白不耐受(LPI)是一种罕见代谢病,因SLC7A7基因变异导致鸟氨酸、赖氨酸和精氨酸的肾脏和肠道重吸收减少。慢性肾脏病常见并可进展至肾衰竭需肾脏替代治疗。本文报告一例LPI患者接受肾移植后蛋白耐受性、血浆和尿中鸟氨酸、赖氨酸、精氨酸水平及LPI症状均获显著改善。
要点
- LPI由SLC7A7基因变异致鸟氨酸、赖氨酸和精氨酸肾脏和肠道重吸收减少。
- LPI患者慢性肾脏病常见,可进展至肾衰竭并启动肾脏替代治疗。
- 本例LPI患者肾移植后蛋白耐受性、血浆和尿氨基酸水平及症状显著改善。
核心结论
- 本例LPI患者肾移植后蛋白耐受性、血浆和尿中鸟氨酸、赖氨酸、精氨酸水平及LPI症状均获显著改善。
研究设计与样本
- 病例报告,描述一例赖氨酸尿性蛋白不耐受患者接受肾移植。
主要发现
- 肾移植后蛋白耐受性显著改善。
- 肾移植后血浆和尿中鸟氨酸、赖氨酸、精氨酸水平显著改善。
- 肾移植后LPI症状显著改善。
局限性
- 原文指出LPI患者肾移植的数据有限,且至今尚无肾移植后临床和生化改善的数据报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lysinuric protein intolerance (LPI) is a rare metabolic disorder with reduced renal and intestinal reabsorption of ornithine, lysine, and arginine. It is due to variants in SLC7A7, the gene encoding y+L amino acid transporter 1 (y+LAT1), which lead to urea cycle defects with protein intolerance. Chronic kidney disease in lysinuric protein intolerance is common and can progress to kidney failure and initiation of kidney replacement therapy. Kidney transplantation could in theory improve urine levels and, consequently, plasma levels of these amino acids and therefore improve clinical symptoms, as well as protein intolerance, in patients with lysinuric protein intolerance. However, data on kidney transplantation in patients with lysinuric protein intolerance are limited, and up until now no data on clinical and biochemical improvement after kidney transplantation have been reported. In this case report we describe a rare case of kidney transplantation in a lysinuric protein intolerance patient with substantial improvement in protein tolerance; in plasma and urine levels of ornithine, lysine, and arginine; and in lysinuric protein intolerance symptoms.
引用
- IJzermans T, van der Meijden W, Hoeks M, et al. Improving a Rare Metabolic Disorder Through Kidney Transplantation: A Case Report of a Patient With Lysinuric Protein Intolerance. Am J Kidney Dis. 2022. PMID: 36223829. doi:10.1053/j.ajkd.2022.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。